Alexandria Real Estate Equities (ARE) has been witnessing a series of strategic successes in its operations. Named one of the most trustworthy companies in America by Newsweek, Alexandria has been focusing on life science mega campuses. The company's recent earnings indicate a 1Q24 net income per share - diluted of $0.97. Brokers have set Alexandria's target price at $136.75, with consensus rating tagged as ‘Moderate Buy’. Alexandria continues to make headway with significant early renewals and lease extensions with notable tenants including insitro, AstraZeneca and Lilly. Despite offloading certain assets, its stock has notably outperformed competitors on strong trading days. Major shareholders like BNP Paribas Financial Markets, CCLA Investment Management, National Bank of Canada FI, and Dimensional Fund Advisors LP have made significant transactions. Notably, Alexandria has provided audiences with action- and solutions-oriented corporate responsibility. FFO and revenue estimates were surpassed in Q4, with the company also declaring a cash dividend of $1.27 per common share for 1Q24. However, some shareholders have trimmed their stake, highlighting a mixed investor sentiment. The firm stands out for its dividend performance, making it a favourable pick for dividend portfolios.
Alexandria Real Estate Equities ARE News Analytics from Fri, 30 Jun 2023 07:00:00 GMT to Thu, 16 May 2024 20:44:01 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
